Candel Therapeutics
An off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.
Founded 1999
Needham, United States
90 employees
Needham, United States
90 employees
General Information
Get notified when Candel Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Candel Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
United States Market
AI Insight
Bounce Watch AICandel Therapeutics has achieved a significant breakthrough with its lead product candidate, CAN-2409. The company recently presented positive pivotal Phase 3 trial findings at #AUA26, followed by their publication in the prestigious The Lancet Oncology. These events represent strong clinical validation and scientific endorsement, significantly de-risking the asset and paving the way for regulatory submissions and potential commercialization.
Signal Types
Clinical Milestone
Scientific Validation
Market Visibility
Strategic Labels
Clinical Validation
Product De-risking
Regulatory Pathway
Next Move:
Regulatory Filing
·
Impact:
9/10
·
Ideal For:
Oncology Biotech Investors – Late Stage
About Candel Therapeutics
No funding data available for Candel Therapeutics yet.
Get notified when Candel Therapeutics raises fundingCandel Therapeutics Alternatives & Competitors
Candel Therapeutics vs
Enterome
France
Delivering the promise of immunotherapy
Series Unknown
49 employees
Biopharma, Biotechnology
Candel Therapeutics vs
DNAtrix
United States
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer....
Series Unknown
3 employees
Biotechnology, Health Care
Candel Therapeutics vs
Genelux
United States
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improvi...
Post Ipo Equity
34 employees
Biopharma, Biotechnology
FAQ About Candel Therapeutics
An off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.
Candel Therapeutics was founded in 1999.
Candel Therapeutics is headquartered in Needham, United States.
Candel Therapeutics has approximately 90 employees.
Top alternatives and competitors to Candel Therapeutics include Enterome, DNAtrix, Genelux, Ultimovacs ASA, OncoResponse. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Candel Therapeutics and Enterome are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors Candel Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.